Cargando…

Use of prostacyclin in pulmonary hypertension

Detalles Bibliográficos
Autores principales:	Vicente, R, López, LM, Ramos, F, Borro, JM, Morales, P, Montero, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 1998
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3301359/ http://dx.doi.org/10.1186/cc247

Ejemplares similares

The pulmonary and haematological toxicity of inhaled aerosolised prostacyclin
por: van Heerden, PV, et al.
Publicado: (1997)

Critical role of pulmonary endothelial production of prostacyclin in the endotoxin-resistant mechanism in mice
por: Okajima, K, et al.
Publicado: (2003)

Role of prostacyclin in pulmonary hypertension
por: Mitchell, Jane A., et al.
Publicado: (2014)

The role of prostacyclin in the interaction of endothelial cells and eosinophil granulocytes
por: Kónya, Viktória, et al.
Publicado: (2008)

Dalteparin reduces ischemia/reperfusion-induced liver injury in rats by increasing the hepatic tissue level of prostacyclin
por: Uchiba, M, et al.
Publicado: (2003)

Clinical and genetic associations with prostacyclin response in pulmonary arterial hypertension
por: Halliday, Stephen J., et al.
Publicado: (2018)

Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension
por: Lang, Irene M., et al.
Publicado: (2015)

Subdural hematomas in pulmonary arterial hypertension patients treated with prostacyclin analogs
por: Louis, Lam, et al.
Publicado: (2012)

Antithrombin reduces the ischemia/reperfusion-induced hepatic injury by increasing hepatic levels of prostacyclin through activation of capsaicin-sensitive sensory neurons in rats
por: Harada, N, et al.
Publicado: (2002)

Treatment of pulmonary hypertension
por: Tagliabue, Paolo, et al.
Publicado: (2014)

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension
por: Colglazier, Elizabeth, et al.
Publicado: (2022)

Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension
por: Kingman, Martha, et al.
Publicado: (2017)

Additional Use of Prostacyclin Analogs in Patients With Pulmonary Arterial Hypertension: A Meta-Analysis
por: Wang, Pengwei, et al.
Publicado: (2022)

Does it exist pulmonary hypertension in the ELBW infants?
por: Dani, Carlo
Publicado: (2015)

Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2022)

Combination Therapy in Pulmonary Arterial Hypertension—Targeting the Nitric Oxide and Prostacyclin Pathways
por: Mandras, Stacy, et al.
Publicado: (2021)

Right ventricular function mirrors clinical improvement with use of prostacyclin analogues in pediatric pulmonary hypertension
por: Hopper, Rachel K., et al.
Publicado: (2018)

Nitric oxide improves pulmonary vascular resistance but not oxygenation in ARDS, heart transplant, and pulmonary hypertension
por: DaSilva, MC, et al.
Publicado: (1998)

Expiratory pressure-volume curves in pulmonary and extrapulmonary ARDS
por: Muñiz Albaiceta, G, et al.
Publicado: (2002)

New Tricks for an Old Drug: Prostacyclins and Right Ventricular Contractility in Pulmonary Arterial Hypertension
por: Wertheim, Bradley M.
Publicado: (2022)

Inhaled therapies targeting prostacyclin pathway in pulmonary hypertension due to COPD: systematic review
por: Alqarni, Abdullah A., et al.
Publicado: (2023)

First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension
por: Geerdink, Lianne M., et al.
Publicado: (2017)

Reversal of Right Ventricular Hypertrophy and Dysfunction by Prostacyclin in a Rat Model of Severe Pulmonary Arterial Hypertension
por: Vanderpool, Rebecca R., et al.
Publicado: (2022)

Role of brief intervention for prenatal alcohol consumption conducted by nonmedical professionals
por: Ancarani, Ornella, et al.
Publicado: (2013)

Induced moderate hypothermia markedly exacerbates pulmonary hypertension and dysoxia in a neonatal piglet model of elevated pulmonary vascular resistance
por: Zayek, MM, et al.
Publicado: (2000)

Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension: A Network Meta-Analysis
por: Zhang, Huijun, et al.
Publicado: (2016)

Resource utilization at the time of prostacyclin initiation in children in pulmonary arterial hypertension: a multicenter analysis
por: Hart, Stephen A., et al.
Publicado: (2018)

Adverse Events of Prostacyclin Mimetics in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
por: Picken, Christina, et al.
Publicado: (2019)

Transitions between infused and oral prostacyclin pathway agents in pulmonary arterial hypertension: key considerations
por: Sargent, Therese, et al.
Publicado: (2020)

Adenosine as pulmonary vasodilator in ARDS
por: Molina, JM, et al.
Publicado: (1998)

The Acute Effects of Prostacyclin on Right Ventricular Contractility and Pulmonary Artery Coupling
por: Vanderpool, Rebecca R., et al.
Publicado: (2023)

The accumulative and maturative type of B-cell activation in synovitis: a new concept of B-cell activation in autoimmune diseases
por: Krenn, VK, et al.
Publicado: (2002)

Specificity of rheumatoid synovial B-cell hybridoma with germline configurated IGVH genes against human nuclear protein histone
por: Morawietz, LM, et al.
Publicado: (2002)

Prostacyclin Regulation of Allergic Inflammation
por: Patel, Kunj, et al.
Publicado: (2022)

Saudi experience in the management of pulmonary arterial hypertension; the outcome of PAH therapy with the exclusion of chronic parenteral prostacyclin
por: Idrees, Majdy, et al.
Publicado: (2015)

Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients
por: Holthaus, Nathan, et al.
Publicado: (2019)

Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy
por: Abu‐Rmaileh, Muhammad, et al.
Publicado: (2023)

Monitoring of hypervolemic hemodilution and hypertensive (HHH) therapy in subarachnoid hemorrhage (SAH) patients with pulmonary artery catheter (PAC)
por: Nates, JL, et al.
Publicado: (1998)

Nitric oxide therapy in persistent pulmonary hypertension of the newborns (PPHN): predictors of survival in a single center experience
por: Maruniak-Chudek, I, et al.
Publicado: (2003)

Evaluating a possible role for PKG1α redox state in chronic hypoxia-induced pulmonary hypertension
por: Rudyk, Olena, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_s2gv5kt6u3gg4vvu3mlb93ipjb